Author: Peter Madrid
-
Repurposing FDA-Approved Drugs to Combat Drug-Resistant Acinetobacter Baumannii
We wanted to identify new scaffolds for drug discovery by repurposing FDA-approved drugs against Acinetobacter baumannii, an emerging Gram-negative nosocomial drug-resistant pathogen.
-
Development and Validation of a High-Throughput Screening Assay for Human Long-Chain Fatty Acid Transport Proteins 4 and 5
The authors used mammalian cell lines stably expressing the recombinant human FATP4 and 5 and developed a high-throughput screening assay using a 96-well fluorometric imaging plate reader.
-
Development of a New Generation of 4-Aminoquinoline Antimalarial Compounds Using Predictive Pharmacokinetic and Toxicology Models
ADMET prediction studies were employed to evaluate a library of new molecules based on the 4-aminoquinolone-related structure of CQ.
-
SU11248 (Sunitinib) Directly Inhibits the Activity of Mammalian 5′-AMP-Activated Protein Kinase (AMPK)
Here we report that the chemotherapeutic drug SU11248 (sunitinib) is at least as potent an inhibitor of AMPK as compound C, which is a commonly used experimental direct inhibitor of the enzyme.